• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Thursday's Pre-Market Session

    12/1/22 8:11:56 AM ET
    $AURA
    $AZYO
    $BCEL
    $BDSX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Medical Specialities
    Health Care
    Get the next $AURA alert in real time by email

    Gainers

    • Otonomy (NASDAQ:OTIC) shares increased by 19.1% to $0.21 during Thursday's pre-market session. The company's market cap stands at $12.2 million.
    • Sigilon Therapeutics (NASDAQ:SGTX) stock moved upwards by 11.51% to $0.44. The market value of their outstanding shares is at $14.2 million.
    • Salarius Pharmaceuticals (NASDAQ:SLRX) shares increased by 11.39% to $2.15. The company's market cap stands at $4.8 million.
    • Personalis (NASDAQ:PSNL) shares rose 10.23% to $2.8. The company's market cap stands at $128.7 million.
    • MEI Pharma (NASDAQ:MEIP) stock moved upwards by 10.22% to $0.38. The market value of their outstanding shares is at $49.9 million.
    • Atreca (NASDAQ:BCEL) shares increased by 9.34% to $1.17. The market value of their outstanding shares is at $45.7 million.

    Losers

    • Aziyo Biologics (NASDAQ:AZYO) shares fell 22.5% to $5.35 during Thursday's pre-market session. The market value of their outstanding shares is at $73.6 million.
    • Aura Biosciences (NASDAQ:AURA) stock declined by 18.42% to $11.65. The market value of their outstanding shares is at $341.7 million.
    • Biodesix (NASDAQ:BDSX) shares fell 17.58% to $1.65. The company's market cap stands at $134.7 million.
    • Corbus Pharmaceuticals (NASDAQ:CRBP) shares fell 12.6% to $0.17. The company's market cap stands at $21.2 million.
    • Biomarin Pharmaceutical (NASDAQ:BMRN) shares declined by 10.88% to $90.0. The market value of their outstanding shares is at $16.7 billion.
    • MSP Recovery (NASDAQ:MSPR) stock fell 9.91% to $1.0. The company's market cap stands at $73.8 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AURA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AURA
    $AZYO
    $BCEL
    $BDSX

    CompanyDatePrice TargetRatingAnalyst
    Biodesix Inc.
    $BDSX
    2/27/2026Mkt Perform → Outperform
    William Blair
    BioMarin Pharmaceutical Inc.
    $BMRN
    1/28/2026$80.00Overweight
    Barclays
    BioMarin Pharmaceutical Inc.
    $BMRN
    1/20/2026$98.00Hold → Buy
    Canaccord Genuity
    BioMarin Pharmaceutical Inc.
    $BMRN
    12/3/2025$60.00Outperform → Market Perform
    Leerink Partners
    Personalis Inc.
    $PSNL
    12/2/2025$11.00Equal-Weight
    Morgan Stanley
    Aura Biosciences Inc.
    $AURA
    11/26/2025$13.00Outperform
    Evercore ISI
    BioMarin Pharmaceutical Inc.
    $BMRN
    11/6/2025$61.00Buy → Hold
    Stifel
    BioMarin Pharmaceutical Inc.
    $BMRN
    9/8/2025$60.00Neutral
    H.C. Wainwright
    More analyst ratings

    $AURA
    $AZYO
    $BCEL
    $BDSX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, Chief Technical Officer Guyer Charles Greg was granted 15,222 shares, increasing direct ownership by 19% to 96,439 units (SEC Form 4)

    4 - BIOMARIN PHARMACEUTICAL INC (0001048477) (Issuer)

    2/26/26 8:49:52 PM ET
    $BMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP, Chief R&D Officer Friberg Gregory R sold $381,937 worth of shares (6,326 units at $60.38), decreasing direct ownership by 14% to 37,578 units (SEC Form 4)

    4 - BIOMARIN PHARMACEUTICAL INC (0001048477) (Issuer)

    2/26/26 8:39:05 PM ET
    $BMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP, Chief Legal Officer Davis George Eric was granted 15,224 shares and sold $1,599,103 worth of shares (26,061 units at $61.36), decreasing direct ownership by 13% to 72,453 units (SEC Form 4)

    4 - BIOMARIN PHARMACEUTICAL INC (0001048477) (Issuer)

    2/26/26 8:31:07 PM ET
    $BMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AURA
    $AZYO
    $BCEL
    $BDSX
    SEC Filings

    View All

    SEC Form S-8 filed by Personalis Inc.

    S-8 - Personalis, Inc. (0001527753) (Filer)

    2/26/26 5:11:47 PM ET
    $PSNL
    Medical Specialities
    Health Care

    SEC Form 10-K filed by Personalis Inc.

    10-K - Personalis, Inc. (0001527753) (Filer)

    2/26/26 4:11:12 PM ET
    $PSNL
    Medical Specialities
    Health Care

    SEC Form 10-K filed by Biodesix Inc.

    10-K - BIODESIX INC (0001439725) (Filer)

    2/26/26 4:06:05 PM ET
    $BDSX
    Medical Specialities
    Health Care

    $AURA
    $AZYO
    $BCEL
    $BDSX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    June 29, 2023 - FDA Approves First Gene Therapy for Adults with Severe Hemophilia A

    For Immediate Release: June 29, 2023 Today, the U.S. Food and Drug Administration approved Roctavian, an adeno-associated virus vector-based gene therapy for the treatment of adults with severe hemophilia A without pre-existing antibodies to adeno-associated virus serotype 5 detected by an FDA-approved test. “Hereditary hemophilia A is a potentially serious bleeding disorder. Severe cases of hemophilia A can ca

    6/29/23 6:02:12 PM ET
    $BMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AURA
    $AZYO
    $BCEL
    $BDSX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $AURA
    $AZYO
    $BCEL
    $BDSX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $AURA
    $AZYO
    $BCEL
    $BDSX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Biodesix upgraded by William Blair

    William Blair upgraded Biodesix from Mkt Perform to Outperform

    2/27/26 8:20:07 AM ET
    $BDSX
    Medical Specialities
    Health Care

    Barclays resumed coverage on BioMarin Pharmaceutical with a new price target

    Barclays resumed coverage of BioMarin Pharmaceutical with a rating of Overweight and set a new price target of $80.00

    1/28/26 7:15:50 AM ET
    $BMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioMarin Pharmaceutical upgraded by Canaccord Genuity with a new price target

    Canaccord Genuity upgraded BioMarin Pharmaceutical from Hold to Buy and set a new price target of $98.00

    1/20/26 8:41:11 AM ET
    $BMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    U.S. Food and Drug Administration Approves BioMarin's PALYNZIQ® (pegvaliase-pqpz) for Adolescents 12 Years of Age and Older with Phenylketonuria (PKU)

    Treatment with PALYNZIQ led to statistically significant blood phenylalanine (Phe) lowering compared to diet alone in pivotal Phase 3 PEGASUS studyPALYNZIQ is the only enzyme substitution therapy approved for the treatment of people with PKUSAN RAFAEL, Calif., Feb. 27, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that the U.S. Food and Drug Administration (FDA) has approved the company's supplemental Biologics License Application (sBLA) for PALYNZIQ® (pegvaliase-pqpz) to include pediatric patients 12 years of age and older with phenylketonuria (PKU). PALYNZIQ is the only enzyme substitution therapy approved to reduce blood phenylalanine (Phe) concentrations

    2/27/26 8:00:00 PM ET
    $BMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Personalis Reports Fourth Quarter and Full Year 2025 Results and Recent Highlights

    Clinical test volume surged 41% in Q4 over Q3 to 6,183 tests and full year increased nearly 400% to 16,233 tests Secured Medicare coverage for breast and lung cancer surveillance, validating ultrasensitive MRD technology Strong cash position of approximately $240 million provides capital for commercial expansion Full year 2026 revenue guidance of $78 to $80 million, driven by expected growth of approximately 5x for clinical revenue Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, today reported financial and operational results for the fourth quarter and full year ended December 31, 2025 and recent business highlights and provided financial

    2/26/26 4:01:00 PM ET
    $PSNL
    Medical Specialities
    Health Care

    Biodesix Announces Fourth Quarter and Fiscal Year 2025 Results and Highlights

    Delivered 41% revenue growth and 83% gross margin in Q4 2025; Improved Net Loss by 52% and achieved first-ever Adjusted EBITDA positivity in Q4 2025; FY2026 Revenue Guidance of $106-112 million, mid-point reflects 23% growth; Conference Call and Webcast Today at 4:30 p.m. ET LOUISVILLE, Colo., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company, today announced its financial and operating results for the fourth quarter and year ended December 31, 2025 (fiscal 2025). "Biodesix delivered exceptional results in the fourth quarter, with revenue of $28.8 million and 83% gross margin," said Scott Hutton, Chief Executive Officer. "We exceed

    2/26/26 4:01:00 PM ET
    $BDSX
    Medical Specialities
    Health Care

    Emeritus Director Schuler Jack W bought $1,180,736 worth of shares (100,000 units at $11.81) (SEC Form 4)

    4 - BIODESIX INC (0001439725) (Issuer)

    1/27/26 9:29:02 AM ET
    $BDSX
    Medical Specialities
    Health Care

    Emeritus Director Schuler Jack W bought $903,561 worth of shares (82,465 units at $10.96) (SEC Form 4)

    4 - BIODESIX INC (0001439725) (Issuer)

    1/26/26 9:28:57 AM ET
    $BDSX
    Medical Specialities
    Health Care

    Director Hanish Arnold C bought $3,740 worth of shares (5,000 units at $0.75) (SEC Form 4)

    4 - Salarius Pharmaceuticals, Inc. (0001615219) (Issuer)

    11/24/25 5:08:13 PM ET
    $SLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AURA
    $AZYO
    $BCEL
    $BDSX
    Leadership Updates

    Live Leadership Updates

    View All

    BioMarin Appoints Arpit Davé Chief Digital and Information Officer

    Mr. Davé Brings more than 20 Years of Experience in Creating Enterprise Value through Digital Transformation, Information Technology and Artificial Intelligence across the Biopharmaceutical Industry SAN RAFAEL, Calif., Jan. 12, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced it has appointed Arpit Davé as Executive Vice President, Chief Digital and Information Officer, a new position reporting directly to President and Chief Executive Officer Alexander Hardy. Mr. Davé will be responsible for reimagining and executing BioMarin's enterprise technology strategy, data science and digital transformation to help create value for patients, employees and shareholders.

    1/12/26 4:05:00 PM ET
    $BMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NovaBridge's Visara Subsidiary Appoints Distinguished Ophthalmology Leaders as Chief Medical Officer and Scientific Advisory Board Chair to Drive VIS-101 Forward

    Cadmus C. Rich, MD, MBA, as Chief Medical Officer, and Carlos Quezada-Ruiz, MD, FASRS, as Chair of the Scientific Advisory Board, bring invaluable clinical development expertise to VIS-101 ProgramThe ability to attract seasoned ophthalmology leaders highlights the compelling opportunity for VIS-101, and underscores our commitment to assembling a world-class teamVIS-101, a novel bifunctional biologic targeting VEGF-A/ANG2, has the potential to become the current standard for wet AMD, DME and RVO, and is expected to be Phase-3-ready in 2026 ROCKVILLE, Md., Nov. 20, 2025 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (NASDAQ:NBP) (NovaBridge or the Company) a global biotechnology platform compa

    11/20/25 8:00:00 PM ET
    $AURA
    $FDMT
    $NBP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    MSP Recovery Announces Strategic Term Sheet Providing Prospective Liquidity and Working Capital Aimed at Driving Future Growth

    MIAMI, Aug. 29, 2025 (GLOBE NEWSWIRE) -- MSP Recovery, Inc. (NASDAQ:MSPR) (the "Company"), a Medicare, Medicaid, commercial, and secondary payer reimbursement recovery and technology leader, announces it has entered into a non-binding term sheet for a new secured term loan facility of up to $55 million. The agreement, with one or more entities managed or advised by, or affiliated with an Investor with whom the Company has signed a non-disclosure agreement, would provide the Company and its affiliates significant working capital and additional operational funding aimed at driving future growth. Additionally, the Investor is committed to pursuing acquisition of additional assignor claim righ

    8/29/25 9:50:09 PM ET
    $MSPR
    EDP Services
    Technology

    $AURA
    $AZYO
    $BCEL
    $BDSX
    Financials

    Live finance-specific insights

    View All

    Biodesix Announces Fourth Quarter and Fiscal Year 2025 Results and Highlights

    Delivered 41% revenue growth and 83% gross margin in Q4 2025; Improved Net Loss by 52% and achieved first-ever Adjusted EBITDA positivity in Q4 2025; FY2026 Revenue Guidance of $106-112 million, mid-point reflects 23% growth; Conference Call and Webcast Today at 4:30 p.m. ET LOUISVILLE, Colo., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company, today announced its financial and operating results for the fourth quarter and year ended December 31, 2025 (fiscal 2025). "Biodesix delivered exceptional results in the fourth quarter, with revenue of $28.8 million and 83% gross margin," said Scott Hutton, Chief Executive Officer. "We exceed

    2/26/26 4:01:00 PM ET
    $BDSX
    Medical Specialities
    Health Care

    BioMarin Reports Fourth Quarter and Full-year 2025 Financial and Operating Results

    Full-year 2025 Total Revenues Increased 13% Y/Y to $3.2 Billion, Led by 9% Revenue Growth for Enzyme Therapies and 26% Revenue Growth for VOXZOGO®Fourth Quarter 2025 Total Revenues Increased 17% Y/Y Led by 13% Revenue Growth for Enzyme Therapies and 31% Revenue Growth for VOXZOGOAnnounced Definitive Agreement to Acquire Amicus Therapeutics, including Galafold® for Fabry Disease and Pombiliti® + Opfolda® for Pompe Disease; Expected to Significantly Accelerate and Diversify RevenuesBioMarin Provides 2026 Guidance Excluding any Post-Close Contribution from the Announced Acquisition of Amicus, Anticipated to Close in Q2'26Conference Call and Webcast Scheduled Today at 4:30 p.m. ETSAN RAFAEL, Cal

    2/23/26 4:05:00 PM ET
    $BMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioMarin to Host Fourth Quarter and Full-Year 2025 Financial Results Conference Call and Webcast on Monday, February 23, 2026, at 4:30pm ET

    SAN RAFAEL, Calif., Feb. 17, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Monday, February 23, 2026, at 4:30 p.m. ET to discuss fourth quarter and full-year 2025 financial results and provide a general business update. Dial-in Number U.S. / Canada Dial-in Number: 800-715-9871International Dial-in Number: 646-307-1963Conference Call ID: 4503000  U.S. / Canada Replay Dial-in Number: 800-770-2030International Replay Dial-in Number: 6

    2/17/26 9:00:00 AM ET
    $BMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AURA
    $AZYO
    $BCEL
    $BDSX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Corbus Pharmaceuticals Holdings Inc.

    SC 13G/A - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Subject)

    11/14/24 7:48:14 PM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Corbus Pharmaceuticals Holdings Inc.

    SC 13G - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Subject)

    11/14/24 6:41:20 PM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Aura Biosciences Inc.

    SC 13G/A - Aura Biosciences, Inc. (0001501796) (Subject)

    11/14/24 5:50:51 PM ET
    $AURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care